MRNA catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 30, 2026Sponsor estimate | NCT05095727A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)ModernaTX, Inc. · Glycogen Storage Disease | MRNALead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT05095727A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)ModernaTX, Inc. · Glycogen Storage DiseaseActive, not recruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 7, 2026Sponsor estimatePhase 4NCT07884175A Study of Updated mRNA Seasonal Influenza VaccinesModernaTX, Inc. · Seasonal InfluenzaRecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimatePhase 1NCT06694753Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in...International AIDS Vaccine Initiative · HIV InfectionsActive, not recruitingMRNACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2026Sponsor estimatePhase 4NCT07863635A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsModernaTX, Inc. · SARS-CoV-2RecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2026Sponsor estimatePhase 1NCT06655870A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy ParticipantsModernaTX, Inc. · Healthy ParticipantsRecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 4NCT06585241A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsModernaTX, Inc. · SARS-CoV-2RecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 28, 2027Sponsor estimate | NCT07496450A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsModernaTX, Inc. · Influenza | MRNALead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 28, 2027Sponsor estimatePhase 3NCT07496450A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsModernaTX, Inc. · InfluenzaActive, not recruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 15, 2027Sponsor estimate | NCT06592794A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute GastroenteritisModernaTX, Inc. · Acute Gastroenteritis | MRNALead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 15, 2027Sponsor estimatePhase 3NCT06592794A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute GastroenteritisModernaTX, Inc. · Acute GastroenteritisActive, not recruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.